Document:

Exhibit 10.27

 

DOMAIN NAME ASSIGNMENT AGREEMENT

 

This Domain Name Assignment Agreement (this “Agreement”),
dated as of July 21, 2004, is made by and between Elan Pharmaceuticals, Inc.,
a Delaware corporation (“Assignor”), and Acorda Therapeutics, Inc.,
a Delaware corporation (“Assignee”).

 

RECITALS

 

WHEREAS, Assignor and Assignee are parties to that
certain Asset Purchase Agreement dated as of July 21, 2004 (the “Asset
Purchase Agreement”);

 

WHEREAS, capitalized terms used herein and not
otherwise defined herein shall have the meanings given to such terms in the
Asset Purchase Agreement;

 

WHEREAS, Assignor has registered and adopted the
Internet domain names set forth on Schedule A attached hereto and
incorporated herein by reference (the “Domain Names”) with Network
Solutions (together with any affiliated or other entity that is responsible for
the registration of domain names in the United States, “NSI”); and

 

WHEREAS, Assignee is acquiring all right, title and
interest in and to the Domain Names from Assignor pursuant to the terms of the
Asset Purchase Agreement.

 

NOW THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto
agree as follows:

 

1.            Subject
to the terms and conditions of the Asset Purchase Agreement and the other Related
Agreements, Assignor does hereby sell, grant, convey, assign, transfer, and
deliver to Assignee, free and clear of any Encumbrances other than Permitted
Encumbrances, all right, title and interest in and the Domain Names and all
goodwill associated therewith.

 

2.             Assignor
covenants and agrees that it shall promptly carry out jointly with Assignee the
formal transfer of the Domain Names to Assignee in accordance with the domain
name transfer procedure of NSI (the “Transfer Procedure”). Assignor
hereby agrees that it shall take such further actions and execute such other
instruments as Assignee may reasonably request to give effect to the foregoing assignment
of the Domain Names, including, but not limited to, such documents as are
necessary to effect the formal transfer of the Domain Names to Assignee in
accordance with the Transfer Procedure.  All
customary costs charged by NSI in connection with the Transfer Procedure shall
be paid solely by Assignee.  In connection
with this transfer, Assignor shall provide any necessary information to NSI or
its designee, including but not limited to, the name or names identified by
Assignee for billing, administrative and technical contacts, to the extent
required by the Transfer Procedures.

 

3.             As
soon as reasonably possible after the date hereof, Assignor will stop all use
of the Domain Names for any purpose, including, but not limited to, use for an
Internet site or for electronic mail.  Assignor shall not adopt any new uses of the
Domain Names.

 

4.             Assignor
shall not use the Domain Names alone or in combination with any other terms,
will Assignor register or use any confusingly similar designation, trademark,
service 

 

 

mark, trade name nor
domain name in connection with the promotion or sale of any service or products
anywhere in world.

 

5.             Assignor
shall not challenge or object to Assignee’s right to register, use, own or
transfer the Domain Names anywhere in the world.

 

6.             Notwithstanding
any other provisions of this Agreement to the contrary, nothing contained in
this Agreement shall in anyway supersede, modify, replace, amend, change,
rescind, waive, exceed, expand, enlarge or in any way affect the provisions,
including warranties, covenants, agreements, conditions, representations or, in
general, any of the rights and remedies, or any of the obligations and indemnifications
of Assignor or Assignee set forth in the Asset Purchase Agreement and the other
Related Agreements.  This Agreement is
intended only to effect the transfer of certain property transferred pursuant
to the Asset Purchase Agreement and the other Related Agreements and shall be governed
entirely in accordance with the terms and conditions of the Asset Purchase
Agreement and the other Related Agreements.

 

7.             This
Agreement shall be governed by and enforced in accordance with and governed by
laws of the State of New York, without giving effect to conflicts of law
principles.

 

8.             This
Agreement shall be binding on, and shall inure to the benefit of, the parties
hereto and their respective successors and assigns.

 

9.             Each
party represents that is has taken all necessary action to authorize the
execution and delivery of this Agreement.

 

10.           This
Agreement may be executed by the parties herein in separate counterparts and by
facsimile, each of which when so executed and delivered shall be an original,
but all such counterparts and facsimiles shall together constitute one and the
same instrument.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

2

 

IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the date first above written.

 

	
   

  	
  ELAN
  PHARMACEUTICALS, INC.

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Jack Laflin

  	
   

  
	
   

  	
   

  	
  Title:

  	
  Executive Vice
  President,

  	
   

  
	
   

  	
   

  	
  Global Core
  Services

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  ACORDA
  THERAPEUTICS, INC.

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Ron Cohen

  	
   

  
	
   

  	
   

  	
  Title:

  	
  President &
  CEO

  	
   

  
						

 

 

[SIGNATURE PAGE TO DOMAIN NAME ASSIGNMENT AGREEMENT]

 

 

SCHEDULE A

 

DOMAIN NAMES

 

1.               ZANAFLEX.COM

2.               ZANAFLEX.ORG

3.               ZANAFLEX.NET

4.               ZANAFLEX
BIZ

5.               ZANAFLEX.US

6.               ZANAFLEX.INFOExhibit
10.28

BILL OF SALE AND
ASSIGNMENT AND ASSUMPTION AGREEMENT

KNOW ALL MEN BY THESE PRESENTS, on this 21st day of
July, 2004, pursuant to the terms of that certain Asset Purchase Agreement
dated as of July 21, 2004 (the “Asset Purchase Agreement”) by and
between Elan Pharmaceuticals, Inc., a Delaware corporation (“Seller”),
and Acorda Therapeutics, Inc., a Delaware corporation (“Buyer”), this
Bill of Sale and Assignment and Assumption Agreement (this “Bill of Sale”)
is being executed and delivered by Seller and Buyer.  The execution and delivery of this Bill of
Sale is a closing delivery requirement pursuant to Section 5.02(a)(i) of the
Asset Purchase Agreement.

NOW, THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto
hereby agree as follows:

1.             Capitalized
terms used herein but not defined herein shall have the meanings assigned to
such terms in the Asset Purchase Agreement.

2.             Subject
to the terms and conditions of the Asset Purchase Agreement and the other
Related Agreements, Seller hereby sells, assigns, transfers and conveys to
Buyer, and Buyer hereby purchases, acquires and accepts from Seller, all of
Seller’s right, title and interest in and to the Purchased Assets, free and
clear of any Encumbrances other than Permitted Encumbrances.

3.             From
time to time after the date hereof, Seller will execute and deliver to Buyer
such instruments of sale, assignment, transfer, conveyance, and delivery, and
such consents, assurances, and other instruments as may be reasonably requested
by Buyer or its counsel in order to vest in the Buyer all right, title and
interest of Seller in and to such Purchased Assets and otherwise in order to
carry out the purpose and intent of this Bill of Sale.

4.             Subject
to the terms and conditions of the Asset Purchase Agreement and the other
Related Agreements, Seller hereby assigns and Buyer hereby accepts and assumes
and agrees to satisfy, perform, pay, honor and discharge when due, all of the
Assumed Liabilities.

5.             Notwithstanding
any other provisions of this Bill of Sale to the contrary, nothing contained in
this Bill of Sale shall in any way supersede, modify, replace, amend, change,
rescind, waive, exceed, expand, enlarge or in any way affect the provisions,
including warranties, covenants, agreements, conditions, representations or, in
general, any of the rights and remedies, or any of the obligations and
indemnifications of Seller or Buyer set forth in the Asset Purchase Agreement
and the other Related Agreements.  This
Bill of Sale is intended only to effect the transfer of certain property
transferred pursuant to the Asset Purchase Agreement and the other Related
Agreements and shall be governed entirely in accordance with the terms and
conditions of the Asset Purchase Agreement and the other Related
Agreements.  Nothing contained in this
Bill of Sale is intended to provide any right or remedy to any person or
entity, other than Seller and Buyer.

6.             This
Bill of Sale shall in all respects be construed in accordance with and governed
by the laws of the State of New York without giving effect to its
conflicts-of-laws principles.

 

7.             This
Bill of Sale may be executed by the parties hereto in separate counterparts and
by facsimile, each of which when so executed and delivered shall be an
original, but all such counterparts and facsimiles shall together constitute
one and the same instrument.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

2

 

IN WITNESS WHEREOF, the parties hereto have caused
this Bill of Sale to be executed and delivered as of the date and year first
above written.

	
   

  	
   

  	
   

  
	
   

  	
  ELAN PHARMACEUTICALS,
  INC.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Jack Laflin

  	
   

  
	
   

  	
  Name:

  	
  Jack Laflin

  
	
   

  	
  Title:

  	
  Executive Vice
  President,

  
	
   

  	
   

  	
  Global Core Services

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  ACORDA THERAPEUTICS,
  INC.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  
	
   

  	
  Title:

  	
   

  

 

[SIGNATURE PAGE TO BILL OF SALE]

 

3

 

IN WITNESS WHEREOF, the parties hereto have caused
this Bill of Sale to be executed and delivered as of the date and year first
above written.

	
   

  	
   

  	
   

  
	
   

  	
  ELAN PHARMACEUTICALS,
  INC.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  
	
   

  	
  Title:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  ACORDA THERAPEUTICS,
  INC.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Ron Cohen

  	
   

  
	
   

  	
  Name:

  	
  Ron Cohen

  
	
   

  	
  Title:

  	
  President and CEO

  

 

 

[SIGNATURE PAGE TO BILL OF SALE]

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]